Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 431-436    https://doi.org/10.1007/s11684-009-0088-4
Research articles
Protective effect of tanshinone II A on signal transduction system protein kinase B in rats with myocardial hypertrophy
Enyuan TU MD,Yongjun PAN MM,Kang ZHENG MM,Zhaohua WANG MD,Qiansheng LIANG MD,Guangtian YANG MD,
Department of Emergency, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;
 Download: PDF(144 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract The effects of tanshinone II A on cell signal transduction system protein kinase B in rats with myocardial hypertrophy induced by the abdominal aorta partial coarctation were investigated. Rat models of myocardial hypertrophy were established by using abdominal aorta partial coarctation method. Forty-eight rats were randomly divided into sham group (S group), model group (M group), valsartan treatment group (X group), low-dose tanshinone treatment group (LD group), medium-dose tanshinone treatment group (MD group), and high-dose tanshinone treatment group (HD group) (n=8 in each group). Left ventricular mass index (LVMI), left ventricular posterior wall (LVPW), and septal thickness (IVS) were detected by high frequency ultrasonography. Myocardial fiber diameter (MFD) was examined by Hematoxylin-Eosin (HE) staining, and the contents of phosphorylated protein kinase B (p-Akt) and p-Gsk3β in myocardium were assayed by Western blot. The results showed that compared with S group, the values of LVMI, LVPW, IVS and MFD were increased in other groups (P<0.05), and the contents of p-Akt, and p-Gsk3β were also increased in other groups. As compared with MD group, the values of LVMI, LVPW, IVS and MFD were decreased in all treatment groups (P<0.05), and the contents of p-Akt, and p-Gsk3β were also decreased in all treatment groups. However, there were no significant differences among LD, MD, and HD groups (P>0.05), and there were no significant differences between X group and tanshinone treatment groups (P>0.05). It was suggested that tanshinone II A could prevent myocardial hypertrophy by its action on the Akt signaling pathway.
Keywords tanshinone II A      myocardial hypertrophy      rat      protein kinase B      abdominal aorta coarctation      
Issue Date: 05 December 2009
 Cite this article:   
Kang ZHENG MM,Qiansheng LIANG MD,Enyuan TU MD, et al. Protective effect of tanshinone II A on signal transduction system protein kinase B in rats with myocardial hypertrophy[J]. Front. Med., 2009, 3(4): 431-436.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0088-4
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/431
Kang Y J. Cardiac hypertrophy: a risk factor for QT2prolon2 gation and cardiacsudden death. Toxicol Pathol, 2006, 34(10): 58–66

doi: 10.1080/01926230500419421
Sun L P, Zheng Z. The effects of sodium tanshinoneII A sulfonate on activation of NF-κB on hypertrophic myocardialcells. Shiyong Laonian Yixue, 2004, 18(1): 25–27 (in Chinese)
Xu S Y, Bian R L, Chen X. Pharmacological experiments methodology. Beijing: People’ HealthPress, 2002, 1026–1028
Frey N, Olson E N. Cardiac hypertrophy: thegood, the bad, and the ugly. Ann Rev Physiol, 2003, 65: 45–79

doi: 10.1146/annurev.physiol.65.092101.142243
James M A, Saadeh A M, Jones J V. Wall stress and hypertension. J Cardiovasc Risk, 2000, 30(7): 187–190
Spirito P, Autore C. Management of hypertrophiccardiomyopathy. BMJ, 2006, 322(7552): 1251–1255

doi: 10.1136/bmj.332.7552.1251
Hu J, Zhang C T, Pu J, Quan X Q, Lv J G, Bai R, Wei Y, Zeng X L. Effects of Perindopril on Ventricular Arrhythmias inRabbits with Cardiac Hypertrophy. Hua ZhongKe Ji Da Xue Xue Bao (Yi Xue Ban), 2008, 37(5): 688–690 (in Chinese)
Ke J, Zhang C T, Ma Y X, Liu J, Liu N, Ruan Y F, Lin L. The Roles of Calmodulin KinaseII Inhibitor in Ventricular Arrhythmias in Rabbits with Cardiac Hypertrophy. Hua Zhong Ke Ji Da Xue Xue Bao (Yi Xue Ban), 2007, 36(2): 183–190 (in Chinese)
Li L F, Chen L W. The mechanisms of myocardialhypertrophy. Hai Nan Yi Xue, 2008, 19(7): 123–125 (in Chinese)
Wang Y. Signaltransduction in cardiac hypertrophy-dissecting compensatory versuspathological pathways utilizing a transgenic approach. Curr Opin Pharmacol, 2001, 41(1): 134–140

doi: 10.1016/S1471-4892(01)00029-7
Morisco C, Zebroski D, Condorelli G. The Akt-glycogen synthase kinase 3β pathway regulatestranscription atrial natriiuretic factor induced by β-adrenergicreceptor stimulation in cardiac myocytes. J Biol Chem, 2000, 275(19): 14466–14475

doi: 10.1074/jbc.275.19.14466
Matsui T, Nagoshi T, Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophyand survival. Cell Cycle, 2003, 2(3): 220–223
Cao W, Shi F X, Phosphodiesterase type 3B:Downstream Factor of PI3k/PKB pathway as well as its clinical research, Xi Bao Sheng Wu Xue Za Zhi, 2007, 29(6): 800–804 (in Chinese)
Frame S, Cohen P. GSK3 takes centre stage morethan 20 years after its discovery. BiochemJ, 2001, 359(1): 1–16

doi: 10.1042/0264-6021:3590001
Antos C L, McKinsey T A, Frey N, Kutschke W, McAnally J, Shelton J M, Richardson J A, Hill J A, Olson E N. Activated glycogen synthase-3β suppresses cardialhypertrophy in vivo. Proc Natl Acad SciUSA, 2002, 99(2): 907–912

doi: 10.1073/pnas.231619298
Shio Jima I, Walsh K. Regulation of cardiac growthand coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev, 2006, 20(24): 3347–3365

doi: 10.1101/gad.1492806
Heineke J, Molkentin J D. Regulation of cardiac hypertrophyby intracellular signaling pathways. NatRev Mol Cell Biol, 2006, 7(8): 589–600

doi: 10.1038/nrm1983
Balakumar P, Singh M. The possible role of caspase-3in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol, 2006, 99(6): 418–424

doi: 10.1111/j.1742-7843.2006.pto_569.x
Gao N, Flynn D C, Zhang Z. G1 cell cycle progression and the expression of G1 cyclinsare regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovariancancer cells. Am J Physiol Cell Physiol, 2004, 287(2): C281–C291

doi: 10.1152/ajpcell.00422.2003
Matsui T, Li L, Wu J C, Cook S A, Naqoshi T, Picard M H, Liao R, Rosenzweiq A. Phenotypix spectrum caused by transgenic overexpressionof activated Akt in the heart. J Biol Chem, 2002, 277(25): 22896–22901

doi: 10.1074/jbc.M200347200
Shioi T, Mcmullen J R, Kang P M, Douqlas P S, Obata T, Franke T F, Cantley L C, Izumo S. Akt/Protein kinase B promotesorgan growth in transgenic mice. Mol CellBiol, 2002, 22(8): 2799–2809

doi: 10.1128/MCB.22.8.2799-2809.2002
McMullen J R, Izumo S. Role of the insulin-likegrowth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediatingphysiological cardiac hypertrophy. NovartisFound Symp, 2006, 274: 90–111

doi: 10.1002/0470029331.ch7
Zhou Y, Zhang J P, Wu M H, Liu H, Zhao Z G, He S Y, Wang Y T, Chu L. Influence of “YiQi QiangXin Decoction” onpressure overload myocardial hypertrophy. Shang Hai Zhong Yi Yao Za Zhi, 2008, 42(5): 80–82 (in Chinese)
Sun L P, Zheng Z. The Effect of Salvia MiltiorrhizaBge on left ventricular hypertrophy and the expression of tumor necrosisfactor-α in spontaneously hypertensive rats. Gao Xue Ya Za Zhi, 2004, 12(3): 238–241 (in Chinese)
Gong L Y, Zheng Z, Xiong W, Sun L P. TanshinoneⅡAprevents angiotensinⅡ-induced hypertrophy of cardiomyocytes from rat. Hua Xi Yao Xue Za Zhi, 2004, 9(1): 24–27 (in Chinese)
Jiang F L, Feng J, Zheng Z. Effect of sodium tanshinone II-Asulfonate on activation of extracellular signal-regulated kinase 1/2in angiotensin II-induced cardiomyocyte hypertrophy. Zhong Guo Yao Li Xue Tong Bao, 2008, 24(3): 307–312 (in Chinese)
Li Y S, Wang Z H, Wang J, Yan L, Yong Y Q, Liang Q S, Zheng Z, Yang G T. Effect of tashinone ⅡA on the nitric oxide synthase geneexpression and intracellular Ca~(2+) level in the hypertrophic cadiocytesof pressure-overloaded rats. Hua ZhongKe Ji Da Xue Xue Bao (Yi Xue Ban), 2008, 37(3): 286–289 (in Chinese)
Yang T, Zhang W, Zhang L. Inhibitory effects of L-arginine-nitric oxide pathwayon formation of pathological cardiac hypertrophy and the related mechanisms. Di Er Jun Yi Da Xue Xue Bao, 2008, 29(2): 177–183 (in Chinese)
Ouyang X, Takahashi K, Komatsu K, Nakamura N, Hattori M, Baba A, Azuma J. Protectiveeffect of salvia miltiorrhiza on angiotensin Ⅱ induced hypertrophicresponses in neonatal rat cardial cells. Jpn J pharmacol, 2001, 87(4): 289–296

doi: 10.1254/jjp.87.289
Pan G J, Wang X L. Effect of Radix Salviae Miltiorrhizae(RAM) on myocardiac hypertrophy in rat model of over-loading pressure. Zhong Guo Fen Zi Xin Zhang Bing Xue Za Zhi, 2007, 7(1): 34–36 (in Chinese)
[1] Ying Huo, Peng Yuan, Qingyuan Qin, Zhiqiang Yan, Liying Yan, Ping Liu, Rong Li, Jie Yan, Jie Qiao. Effects of vitrification and cryostorage duration on single-cell RNA-Seq profiling of vitrified-thawed human metaphase II oocytes[J]. Front. Med., 2021, 15(1): 144-154.
[2] Wenwen Shang, Lei Wu, Rui Xu, Xian Chen, Shasha Yao, Peijun Huang, Fang Wang. Clinical laboratory features of Meigs’ syndrome: a retrospective study from 2009 to 2018[J]. Front. Med., 2021, 15(1): 116-124.
[3] Jing Ma, Shiyu Chen, Lili Hao, Wei Sheng, Weicheng Chen, Xiaojing Ma, Bowen Zhang, Duan Ma, Guoying Huang. Long non-coding RNA SAP30-2:1 is downregulated in congenital heart disease and regulates cell proliferation by targeting HAND2[J]. Front. Med., 2021, 15(1): 91-100.
[4] Xiaofang Cai, Hanlan Jiang, Simin Zhang, Shengying Xia, Wenhui Du, Yaoling Ma, Tao Yu, Wenbin Li. Clinical manifestations and pathogen characteristics in children admitted for suspected COVID-19[J]. Front. Med., 2020, 14(6): 776-785.
[5] Lingling Tang, Yingan Jiang, Mengfei Zhu, Lijun Chen, Xiaoyang Zhou, Chenliang Zhou, Peng Ye, Xiaobei Chen, Baohong Wang, Zhenyu Xu, Qiang Zhang, Xiaowei Xu, Hainv Gao, Xiaojun Wu, Dong Li, Wanli Jiang, Jingjing Qu, Charlie Xiang, Lanjuan Li. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19[J]. Front. Med., 2020, 14(5): 664-673.
[6] Huiwen Ren, Can Wu, Ying Shao, Shuang Liu, Yang Zhou, Qiuyue Wang. Correlation between serum miR-154-5p and urinary albumin excretion rates in patients with type 2 diabetes mellitus: a cross-sectional cohort study[J]. Front. Med., 2020, 14(5): 642-650.
[7] Allison J. Navarrete-Welton, Daniel A. Hashimoto. Current applications of artificial intelligence for intraoperative decision support in surgery[J]. Front. Med., 2020, 14(4): 369-381.
[8] Xuran Chu, Chengshui Chen, Chaolei Chen, Jin-San Zhang, Saverio Bellusci, Xiaokun Li. Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors[J]. Front. Med., 2020, 14(3): 262-272.
[9] Guangbiao Zhou, Saijuan Chen, Zhu Chen. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies[J]. Front. Med., 2020, 14(2): 117-125.
[10] Wei Liu, Jing Wang, Wenbin Li, Zhaoxian Zhou, Siying Liu, Zhihui Rong. Clinical characteristics of 19 neonates born to mothers with COVID-19[J]. Front. Med., 2020, 14(2): 193-198.
[11] Jie Pan, Zhengchao Shi, Dingsai Lin, Ningmin Yang, Fei Meng, Lang Lin, Zhencheng Jin, Qingjie Zhou, Jiansheng Wu, Jianzhong Zhang, Youming Li. Is tailored therapy based on antibiotic susceptibility effective ? A multicenter, open-label, randomized trial[J]. Front. Med., 2020, 14(1): 43-50.
[12] Yuan Gao, Zhilei Wang, Jinfa Tang, Xiaoyi Liu, Wei Shi, Nan Qin, Xiaoyan Wang, Yu Pang, Ruisheng Li, Yaming Zhang, Jiabo Wang, Ming Niu, Zhaofang Bai, Xiaohe Xiao. New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front. Med., 2020, 14(1): 68-80.
[13] Seo Yeon Baik, Hyunah Kim, So Jung Yang, Tong Min Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim. Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea[J]. Front. Med., 2019, 13(6): 713-722.
[14] Jiajia Hu, Wenbin Shen, Qian Qu, Xiaochun Fei, Ying Miao, Xinyun Huang, Jiajun Liu, Yingli Wu, Biao Li. NES1/KLK10 and hNIS gene therapy enhanced iodine-131 internal radiation in PC3 proliferation inhibition[J]. Front. Med., 2019, 13(6): 646-657.
[15] Mara Simopoulou, Konstantinos Sfakianoudis, Petroula Tsioulou, Anna Rapani, Polina Giannelou, Nikolaos Kiriakopoulos, Agni Pantou, Nikolaos Vlahos, George Anifandis, Stamatis Bolaris, Konstantinos Pantos, Michael Koutsilieris. What will the future hold for artificial organs in the service of assisted reproduction: prospects and considerations[J]. Front. Med., 2019, 13(6): 627-638.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed